Extensive alterations of blood metabolites in pediatric cerebral malaria

Sanchit Gupta1, Karl Seydel2,3, Miguel A. Miranda-Roman1, Catherine M. Feintuch4, Alex Saidi2, Ryung S. Kim5, Gretchen L. Birbeck6, Terrie Taylor2,3, Johanna P. Daily1,4,*

1 Department of Medicine, Division of Infectious Disease, Albert Einstein College of Medicine, Bronx, New York, United States of America, 2 Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi, 3 Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States of America, 4 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America, 5 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, United States of America, 6 Department of Neurology, Epilepsy Division, University of Rochester, Rochester, New York, United States of America

* jdaily@einstein.yu.edu

Abstract

Cerebral malaria (CM) presents as an encephalopathy and is due to infection with Plasmodium falciparum. Patients are comatose, often with fever, recurrent seizures and this condition is associated with a high mortality rate. The etiology of the coma and seizures are poorly understood. Circulating small molecules and lipids have bioactive functions and alterations in their concentrations have been implicated in seizure disorders and other forms of encephalopathy. We carried out a comprehensive analysis of blood metabolites during CM to explore a biochemical basis of this encephalopathy. A paired metabolomics analysis was performed on the plasma samples of Malawian children (n = 11) during CM and at convalescence thirty days later, to identify differentially abundant molecules associated with CM. We also report plasma molecules associated with CM mortality (n = 4) compared to survival (n = 19). Plasma metabolites were identified through ultra high performance liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry to maximize compound detection and accuracy and then compared to a library for identification. We detected a total of 432 small molecules in the plasma and 247 metabolites were significantly differentially abundant between CM and convalescence (p < 0.05, FDR < 0.10). These represented global changes across many classes of molecules including lipids, amino acids and hemoglobin metabolites. We observed significant changes in molecules that could impact neurologic function during CM; these include increased levels of kynurenate and decreased indolepropionate, glutamate, arginine and glutamine. Moreover, 1-methylimidazoleacetate, kynurenate, arachidonic acid and dimethylarginine were associated with mortality (p < 0.05, fold change > 1.2). These results highlight the broad changes in blood chemistry during CM. We have identified metabolites that may impact central nervous system physiology and disease outcomes and can be further explored for their mechanistic roles into the pathophysiology of CM.
Introduction

Despite improvements in clinical care and vector control, *Plasmodium falciparum* malaria remains a disease of global importance, with 214 million cases worldwide and 438,000 deaths, mostly among children in Africa [1]. Cerebral malaria (CM), a severe complication of *P. falciparum* infection is heralded by coma, and a high prevalence of recurrent seizures and status epilepticus [2]. The encephalopathy and seizures typically resolve within 2–3 days in conjunction with antimalarial treatment and supportive care, but 25% of pediatric CM survivors develop long term neurological sequelae including epilepsy [3]. The mechanisms of seizure and coma in CM remain poorly understood.

The rapid onset and resolution of the coma of CM are consistent with a metabolic cause. Metabolic changes in blood are common during CM and include hypoglycemia and hyperlactatemia, though a comprehensive analysis has not been reported [4]. Changes in blood composition reflect the physiology of a severe *P. falciparum* infection which is associated with high levels of inflammation, hemolysis and the presence of parasite derived metabolites. Local tissue hypoxia due to microvascular compromise from sequestration of infected red blood cells (iRBC) to vascular endothelial cells further impacts blood metabolite levels. Taken together, we hypothesized that significant changes in the blood metabolome occur during CM, and that these changes could impact normal brain functions. To examine the potential role of small molecules and lipids in the clinical findings of CM we carried out a comprehensive, unbiased plasma metabolomics association study in a cohort of Malawian children with CM during coma and during a convalescent state thirty days later.

Materials and methods

Study population

Study subjects were Malawian children aged 6 months to 12 years enrolled in the Blantyre Malaria Project (BMP), who presented with CM during the malaria transmission season January through June 2013 [5, 6]. Study subjects had a Blantyre Coma Score \( \leq 2 \), with no other identified cause of coma such as hypoglycemia, bacterial meningitis or a post ictal state. Children who fulfilled the WHO case definition of CM and had evidence of iRBC brain microvasculature sequestration determined by the presence of retinopathy were studied [5]. Patients were excluded from the analysis if they were HIV positive, determined by two rapid tests: Uni-Gold (Trinity Biotech) and Determine (Inverness Medical). Upon enrollment, venous blood samples were collected in EDTA collection tubes, and plasma was separated by centrifugation and maintained at -80°C. Study subjects were treated with intravenous quinine (in accordance with Malawi government treatment guidelines at that time), provided supportive care during their hospitalization and were negative for parasitemia on blood smears, prior to discharge from the research ward. Study survivors presented for follow up one month later and underwent a physical exam, blood smear and a repeat venipuncture to obtain a convalescent plasma sample. Clinical and laboratory data were extracted from the study subjects’ record. The study was approved by The University of Malawi College of Medicine Research and Ethics Committee, and by the Institutional Review Boards of Michigan State University and Albert Einstein College of Medicine. Written informed consent was obtained from the accompanying parent or guardian of the study subjects.

Metabolomic analysis

To identify blood metabolites, a non-targeted metabolomics analysis was carried out on plasma using ultra high performance liquid chromatography/tandem mass spectrometry in
both positive and negative ion modes and gas chromatography/mass spectrometry to maximize compound detection and accuracy (Metabolon, Durham, NC). Metabolites were identified by comparing the experimental samples’ spectral signatures to a reference library dataset [7]. The data provide relative molecule abundance represented by ion counts. We then quantified and validated a subset of molecules that demonstrated significant differences using AbsoluteIDQ™ (BIOCRATES Life Sciences AG, Innsbruck, Austria) on an UPLC-MS/MS platform (Acquity UPLC- Xevo TQ MS, Waters Corporation, Milford, MA, USA) using methods as described [8]. This assay also quantified phospholipids and sphingolipids. Metabolites with a covariance less than 20% are reported.

Statistical analysis

The primary outcome was to identify plasma small molecules that were significantly differentially abundant during CM compared to the paired convalescent sample, and the secondary outcome was small molecules associated with mortality. Ion counts were generated for each metabolite and the metabolite was retained in the analysis if it was detected in 50% or more samples from either the CM or convalescent group. After this filter, minimum values across all groups were imputed for any remaining data below the detection threshold. Fold change for abundance was calculated relative to the CM sample as compared to the matched convalescent value, and in death relative to survival in the mortality analysis. Ion count values were log2--transformed and analyzed by paired t-test for the CM-convalescent comparison, and t-test with Welch approximation for the mortality analysis. The false discovery rate (FDR) was calculated for each metabolite for both comparisons. We defined significant metabolites as having a \( p < 0.05 \) and \( \text{FDR} < 0.10 \) comparing paired CM and convalescent samples. For the survival analysis we used a \( p < 0.05 \) without a FDR due to the low number of deaths. Comparisons of CM and convalescence plasma amino acid concentrations were performed using the Wilcoxon matched-pairs signed rank test. Analyses were carried out with R v3.1.1 (http://cran.r-project.org/), Stata v13.0 (StatCorp, College Station, TX) and Graph Prism (GraphPad Software, La Jolla, CA). GenePattern (http://www.broadinstitute.org/cancer/software/genepattern/) was used for hierarchical clustering analysis and heat map generation [9].

Results

Characteristics of the study cohort

During the 2013 transmission seasons, plasma samples were collected on admission from 43 pediatric patients with CM and from 31 survivors on day 30 post-admission. Eleven patients without retinopathy were excluded. Twenty-three CM patient plasma samples were randomly selected for metabolomics analysis (Table 1). The demographics, laboratory data and outcomes of this subset were not statistically different from the entire cohort (data not shown). The twenty-three subjects manifested fever, coma, tachycardia, anemia and thrombocytopenia reflective of CM. Four patients (17%) died, and at the time of discharge, 17% (4) of the analyzed subjects sustained neurologic sequelae such as deficits in vision, hearing, or motor function.

To identify the blood metabolite profiles during CM compared to convalescence, we randomly selected eleven paired plasma samples. During the convalescent study visit, all eleven subjects were afebrile, awake and overall clinically well. The median convalescent hematocrit of 35% was significantly increased from the enrollment hematocrit of 23% (\( p = 0.008 \)). Patient number 5 presented to the convalescent visit with a two-day history of fever. At the time of the exam he was afebrile, fully conscious, with a non-focal exam, however he had a 4+ positive (semi-quantitative measurement, 1+ to 5+) peripheral blood parasitemia. He was treated with
an oral antimalarial. All of the other patients were blood smear negative. Patient 6 reported one week of diarrhea and was afebrile with a non-focal exam.

Blood metabolite differences during CM compared to paired convalescence samples

We detected a total of 432 metabolites of which 393 remained after filtering out infrequently detected molecules in the eleven paired samples. Of the 393 metabolites, 247 were statistically significantly differentially abundant ($p < 0.05$, FDR $< 0.10$) between CM and convalescence. These differentially abundant molecules represented diverse chemical classes, including 59 amino acids, 11 carbohydrates, 10 cofactors and vitamins, 4 tricarboxylic cycle acid (TCA) cycle intermediates, 120 lipids, 12 nucleotides, 8 peptides, and 23 xenobiotics (S1 Table).

Unsupervised hierarchical clustering of these 247 metabolites completely segregated the samples by CM and convalescence (Fig 1). Notably, the metabolome derived from the convalescent sample (patient 5) who had mild malaria clustered with the convalescent samples.

Amino acids and their metabolites were both enriched and depleted during CM. Alpha-ketobutyrate and 2-hydroxybutyrate, degradation products of threonine and methionine metabolism, were highly enriched during CM (S1 Table). We quantified and validated the increase in a subset of amino acids during CM, including branched chained amino acids leucine (211 µM vs 80 µM, $p = 0.008$) and valine (317 µM vs 117 µM, $p = 0.008$) (Fig 2). Phenylalanine was also increased during CM (128 µM vs 54 µM, $p = 0.008$), as was tryptophan (53 µM vs 30 µM, $p = 0.016$). Phenylalanine metabolites 3-(4-hydroxyphenyl) lactate, phenyllactate and N-acetylsymbolphaenylalanine were also enriched during CM, along with tryptophan metabolites kynurenine (6.4 µM vs 1.7 µM, $p = 0.008$), kynurenate and indolelactate (S1 Table).
During CM, we found a depletion in amino acids including arginine (41 µM vs 61 µM, p = 0.109), glutamate (36 µM vs 80 µM, p = 0.078) and glycine (131 µM vs 278 µM, p = 0.008) (Fig 2). Citrulline (11 µM vs 27 µM, p = 0.008) and ornithine (19 µM vs 48 µM, p = 0.008), metabolic precursors for arginine, the principle substrate for nitric oxide production, were also depleted during CM. Indolepropionate, a tryptophan derivative that acts as a neuroprotective free-radical scavenger, demonstrated a large reduction during CM (S1 Table) [10].

The study subjects were anemic during CM, with a median hematocrit of 21%. Red cell lysis was reflected with a significant enrichment of heme metabolites during CM including elevated biliverdin, bilirubin, L-urobilin, and I-urobilinogen (S1 Table).

Notably there was a generalized enrichment of fatty acids during CM, including 12 polyunsaturated fatty acids and 15 medium and long chain fatty acids with concomitant reduction in lysolipids (Fig 3, S1 Table). Arachidonic acid, which is mobilized from membrane lipids by phospholipase A2 (PLA2) and is a precursor for a wide variety of inflammatory mediators such as eicosanoids, was increased during CM compared to convalescence. To further explore and quantify the decrease in complex lipids, we carried out a quantitative analysis in 8 of the 11 paired samples and found a significant depletion of 22 lysolipids and enrichment of 5 species of phosphatidylcholine during CM (p < 0.05, FDR < 0.10) (Fig 3, S2 Table).

During CM, bile acids were broadly enriched and alterations in relative contribution of each bile acid to the total bile acid pool was detected (S3 Table) [11]. Four gamma-glutamyl moieties and thirteen steroids, including cortisone, cortisol and pregnenolone sulfate, were elevated during CM (S1 Table). Quinine and acetaminophen were detected during CM secondary to malaria treatment.
Plasma molecules associated with mortality

To identify metabolites associated with mortality, we compared the CM metabolome dataset between fatal cases (n = 4) and survivors (n = 19). 363 metabolites were assessed after filtering, and 19 were significantly associated with death (p < 0.05), including 1-methylimidazoleacetate, kyurenate, arachidonic acid and dimethylarginine (p < 0.05, fold change > 1.2, Table 2).

**Fig 2.** Plasma amino acid concentrations during CM compared to convalescence. Selected plasma amino acid concentrations during CM and at convalescence (one month later) in eleven children. (A) Enriched amino acids during CM. (B) Depleted amino acids during CM. Scatter plots show median and interquartile ranges. A Wilcoxon matched-pairs signed rank test was performed. * represents P<0.05; ** represents P<0.01.

https://doi.org/10.1371/journal.pone.0175686.g002

Plasma molecules associated with mortality

To identify metabolites associated with mortality, we compared the CM metabolome dataset between fatal cases (n = 4) and survivors (n = 19). 363 metabolites were assessed after filtering, and 19 were significantly associated with death (p < 0.05), including 1-methylimidazoleacetate, kyurenate, arachidonic acid and dimethylarginine (p < 0.05, fold change > 1.2, Table 2).
Fig 3. Enrichment in fatty acids, sterols, bile acids and other lipids during CM compared to convalescence. A bar graph of the number of differentially abundant lipids (paired t test, p-value < 0.05, FDR < 0.10) by lipid class during CM compared to convalescence (n = 11 paired samples). We found marked reduction in the number of phospholipids and lysolipids during infection and enrichment in fatty acids. * denotes data obtained from a quantitative metabolomic method (n = 8 paired samples).

https://doi.org/10.1371/journal.pone.0175686.g003

Table 2. Blood metabolites associated with mortality in CM (n = 23).

| Molecule                          | Pathway                                 | P value    | Fold change |
|----------------------------------|-----------------------------------------|------------|-------------|
| 5-hydroxyhexanoate               | Fatty Acid, Monohydroxy                 | 4.7E-02    | 2.17        |
| palmitoyl ethanolamide           | Endocannabinoid                         | 2.6E-02    | 1.86        |
| docosadienoate (22:2n6)          | Polysaturated Fatty Acid (n3 and n6)    | 2.8E-02    | 1.84        |
| kynurenate                       | Tryptophan Metabolism                   | 5.3E-03    | 1.78        |
| 1-methylimidazoleacetate         | Histidine Metabolism                    | 3.8E-03    | 1.51        |
| arginine                         | Urea cycle; Arginine and Proline Metabolism | 1.1E-02    | 1.51        |
| N-acetyltreonine                 | Glycine, Serine and Threonine Metabolism | 2.3E-02    | 1.46        |
| 17-methylstearate                | Fatty Acid, Branched                    | 1.2E-02    | 1.42        |
| gluconate                        | Food Component/Plant                    | 3.2E-02    | 1.34        |
| acisoga                          | Polyamine Metabolism                    | 3.6E-02    | 1.32        |
| arachidonic acid (20:4n6)        | Polysaturated Fatty Acid (n3 and n6)    | 8.0E-03    | 1.25        |
| dimethylarginine (SDMA + ADMA)   | Urea cycle; Arginine and Proline Metabolism | 4.7E-02    | 1.20        |
| arabinose                        | Pentose Metabolism                      | 2.4E-02    | 1.18        |
| uridine                          | Pyrimidine Metabolism, Uracil containing | 1.7E-02    | 1.14        |
| urea                             | Urea cycle; Arginine and Proline Metabolism | 4.5E-02    | 1.13        |
| valine                           | Leucine, Isoleucine and Valine Metabolism | 2.8E-02    | 0.73        |
| 3-phenylpropionate (hydrocinnamate) | Phenylalanine and Tyrosine Metabolism       | 4.0E-05    | 0.30        |
| taurolithocholate 3-sulfate       | Secondary Bile Acid Metabolism           | 1.8E-02    | 0.22        |
| 1,2-propanediol                  | Chemical                                 | 4.4E-02    | 0.10        |

Plasma metabolites collected during CM were compared between 4 non-survivors and 19 survivors. Fold change represents the ratio of non survivors to survivors. Ion counts were log2-transformed and analyzed for significance by t-test with Welch approximation.

https://doi.org/10.1371/journal.pone.0175686.t002
Discussion

CM is a severe systemic disease associated with an encephalopathy, seizures and mortality. To examine a potential role of small molecules in the pathophysiology of pediatric CM we characterized the blood metabolomes during CM compared to convalescence. We identified greater than two hundred small molecules and lipids that were significantly altered during pediatric CM reflecting global blood chemistry dysregulation. Both parasite and host metabolism likely contributes to these changes during CM. A large sequestered biomass of parasites utilize host nutrients including carbons, lipids, purines and amino acids and these processes are accompanied by a catabolic inflammatory host response to alter the blood chemical landscape [12]. Some of the depleted molecules have important neuroprotective roles, such as indolepropionate and the depletion of other molecules such as glutamate can impair immunologic function. More broadly, we noted a marked depletion of complex phospholipids and an enrichment in fatty acids representing an increase in energetic needs and evidence of liver dysfunction suggested by increases in bile acids. These data provide new insights into the pathophysiology and potential biochemical etiologies of the neurological manifestations and mortality of CM.

Neurologic implications

Seizures commonly occur during CM and the development of epilepsy post CM is prevalent. In other conditions, metabolic causes of seizures are associated with abnormal levels of amino acids, purines, carbohydrates, acylcarbamates and urea cycle defects [13]. We found changes in small molecules levels during CM that have been implicated in seizure and/or encephalopathies, including increases in kynurenate and the branch chain amino acids leucine and valine [14]. We also noted a modest elevation in phenylalanine (2.6 fold increase), which has been reported in children and adults with CM and other forms of severe malaria compared to controls [15]; however, the blood concentrations did not approach those seen in phenylketonuria, which results in seizures and other neurological symptoms [16]. Oxidative stress may contribute to the development of epilepsy, as compounds with antioxidant properties prevent seizure induced pathology [17]. A number anti-oxidants were depleted during CM including indolepropionate a neuroprotective free-radical scavenger which has been shown to provide a neuroprotective effect in an animal model of ischemia along with the glutathione precursors, glutamate, and glycine [18]. Thus a reduction in molecules that combat oxidative stress may contribute to the high prevalence of seizures and post CM epilepsy [16]. Glutamate plasma levels were lower during CM compared to convalescence. This amino acid provides cellular energy and low levels can impair white blood cell function [19]. Treatment with glutamate could potentially improve outcomes as supplemental glutamate increased survival in the animal model of cerebral malaria through modulation of CD8+ effector T cell function [20].

Hemoglobin metabolism and liver disease

We observed elevated heme degradation products including bilirubin, biliverdin and urobilinogen during CM. Heme is metabolized to biliverdin, then to bilirubin which is transported to the gastrointestinal tract and further metabolized by gut microbe to urobilinogen. Elevations in heme metabolites can reflect the increase in heme metabolism due the hemolysis of malaria infection and/or liver injury [21]. The enrichment of gamma-glutamyl amino acids may indicate increased activity of gamma-glutamyl transferase, which is associated with liver disease [22]. High levels of bilirubin can cause neurotoxicity (kernicterus), though the impact of its downstream metabolites on brain function is unknown. Bile salts, which facilitate hepatobiliary secretion of lipids, and act as signaling molecules in metabolism and immune responses, were dysregulated during CM, and may also reflect liver disease [23]. Autopsy
studies of pediatric CM have identified extensive Kupffer cell hyperplasia with accumulation of malaria pigment and mild portal and lobular lymphocytic infiltration, however there are only minimal signs of cellular necrosis or cholestasis [24]. Perhaps this unique pathology of the biliary system is sufficient to alter plasma bile salt concentrations. Individual bile salts have distinctive bioactive properties and can impact the blood brain barrier and neurologic function [25–27].

More broadly, we found a high level of ketone bodies, and an enrichment of fatty acids, with a decrease in lysolipids suggesting a shift to fatty acid metabolism, likely due to increased energetic needs [28]. High levels of catecholamines and pro-inflammatory cytokines during severe malaria may drive the enhanced lipolysis and de novo synthesis of fatty acids to be used for oxidative metabolism [29]. Liver stage parasites require phosphatidylcholine for growth and this may also contribute to decreased blood levels [30]. A study in the murine model of malaria found that blood lipoprotein profiles segregate animals that go on to cerebral as compare to non-cerebral malaria, at a time point prior to onset of neurologic symptoms, suggesting that lipid alterations may also be playing a role in neurologic function [31].

The reductions in plasma glycine, cysteine, serine, threonine and glutamine during CM could be secondary to parasite uptake and/or host utilization [32]. Arginine was low during CM, and its depletion plays an important role in the vasculopathy of CM [33]. Endothelial dysfunction may be further compounded by high blood levels of dimethylarginine, which can inhibit NO synthesis and was associated with death in our study [34].

**Biomarkers of mortality**

We identified common changes in blood chemistry during CM and those reported in sepsis, which is also associated with inflammation and heightened mortality. Sepsis is also associated with an increase in 2-hydroxybutyrate, phenylalanine and decrease in glutamine, 1-arachidonylglycerophosphocholine and 1-linoleoylglycerophosphocholine [35, 36]. Furthermore, elevated levels of kynurenate, 1-methylimidazoleacetate and dimethylarginine are associated with mortality in both conditions [37–39]. 1-methylimidazoleacetate is a histamine metabolite and histamine elevations have been previously reported during CM [40]. Histamine has been implicated in murine models of CM, with histamine receptor inhibition providing a protective effect [41]. A sepsis study and our data both found metabolites of PLA2 to be associated with death (1-arachidonoyl-GPE (20:4), 1-arachidonoyl-GPC (20:4) in sepsis, and arachidonic acid in CM) [37]. Despite the many shared clinical and biochemistry features between CM and sepsis, the neurological symptoms are unique to CM and thus the study of small molecules specifically associated with CM could provide mechanistic insights into CM associated seizures and coma.

One limitation of this study is the small sample size associated with death, and larger prospective studies are needed. Furthermore, our metabolomics method does not capture all molecules. Parasites can generate unique metabolites and thus additional extraction and analytic methods using unsupervised methods would be needed [42]. Understanding the impact of alterations of the metabolome in asymptomatic or mild malaria would require additional comparative analysis of these clinical phenotypes. Whether changes in single molecule or a combination of molecules in the setting of fever lowers the seizure threshold and/or contributes to the encephalopathy of CM is unknown. Longitudinal studies of children with CM with frequent blood sampling and small molecule correlations to mental status and EEG monitoring are underway to parse which molecules may be playing a role in the neurological manifestations of CM.

**Conclusions**

Collectively, these data represent the first wide-scale blood metabolomics analysis during pediatric CM. Previous studies of blood chemistry during malaria infection malaria have been
limited, with most using *in vitro* or animal models of disease, and none examining pediatric CM plasma. We see evidence of global changes across metabolite classes, many of which play important roles in human physiology. We found alterations in fatty acid metabolism and lipid distributions reflecting changes also described in sepsis and critical illness. Alterations in kynurenate, glutathione precursors, and glutamine may be involved in mediating encephalopathy and/or altering seizure thresholds. Further clinical and mechanistic studies are needed to understand the role of small molecules on neurologic function and mortality in CM to improve outcomes.

**Supporting information**

**S1 Table.** List of blood metabolite differences during CM compared to convalescence in a paired analysis. The 247 plasma small molecules that demonstrated statistically significantly differentially abundant ion counts (p < 0.05, FDR < 0.10) between CM and convalescence in eleven paired plasma samples are presented. (XLSX)

**S2 Table.** Quantification of blood lipids and other metabolites during CM compared to convalescence samples in a paired analysis. To quantify the changes in lipids and other selected metabolites, we carried out a quantitative analysis using AbsoluteIDQ™ (BIOCRATES Life Sciences AG, Innsbruck, Austria) on an UPLC-MS/MS platform (Acquity UPLC- Xevo TQ MS, Waters Corporation, Milford, MA, USA) in eight pairs. Plasma concentrations, P values, FDR and fold changes are reported between CM and convalescence for all metabolites measured. (XLSX)

**S3 Table.** Differences in blood bile acids during CM compared to convalescence. Differences in ion counts, P values, FDR and fold changes are reported for bile acids in 11 paired plasma samples during CM and convalescence thirty days later. (DOCX)

**Author Contributions**

**Conceptualization:** SG KS MR RSK GB TT JPD.

**Formal analysis:** SG RSK JPD.

**Funding acquisition:** JPD.

**Investigation:** SG CMF AS MR.

**Project administration:** SG KS TT JPD.

**Resources:** KS TT RSK.

**Supervision:** KS TT JPD.

**Visualization:** SG RSK JPD.

**Writing – original draft:** SG JPD.

**References**

1. WHO. World Malaria Report. Geneva, Switzerland: World Health Organization. 2015.
2. Birbeck GL, Molyneux ME, Kaplan PW, Seydel KB, Chimalizeni YF, Kawaza K, et al. Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. The Lancet Neurology. 2010; 9(12):1173–81. Epub 2010/11/09. PubMed Central PMCID: PMCP2988225. https://doi.org/10.1016/S1474-4422(10)70270-2 PMID: 21056005

3. Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res. 2010; 68(4):267–74. PubMed Central PMCID: PMC3065312. https://doi.org/10.1203/00006450-20101101-00524 PMID: 20666900

4. Grau GE, Craig AG. Cerebral malaria pathogenesis: revisiting parasite and host contributions. Future Microbiol. 2012; 7(2):291–302. https://doi.org/10.2217/fmb.11.155 PMID: 22324996

5. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JG, Fosiko NG, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nature medicine. 2004; 10(2):143–5. https://doi.org/10.1038/nnm986 PMID: 14745442

6. Pappa V, Seydel G, Gupta S, Feintuch CM, Potchen MJ, Kampondeni S, et al. Lipid metabolites of the phospholipase A2 pathway and inflammatory cytokines are associated with brain volume in paediatric cerebral malaria. Malaria journal. 2015; 14(1):1.

7. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultra-high-performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Analytical chemistry. 2009; 81(16):6656–67. https://doi.org/10.1021/ac901536h PMID: 19624122

8. Römisch-Margl W, Prehn C, Bogumil R, Röhring C, Suhr K, Adamski J. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics. 2012; 8(1):133–42.

9. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nature genetics. 2006;38(5):500–1. https://doi.org/10.1038/ng0506-500 PMID: 16642009

10. Chyan Y-J, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, et al. Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. Journal of Biological Chemistry. 1999; 274(31):21937–42. PMID: 10419156

11. Monta T, Matsuyama Y, Fujimoto T, Higuchi M, Tsujii T, Matsuoka Y. Clinical significance of serum bile acid measurement in liver diseases. Gastroenterologia Japonica. 1978; 13(6):491–502. PMID: 748093

12. Sherman IW. Biochemistry of Plasmodium (malarial parasites). Microbiological reviews. 1979; 43(4):453–95. PubMed Central PMCID: PMC281489. PMID: 94424

13. Papetti L, Parisi P, Leuzzi V, Nardecchia F, Nicita F, Ursitti F, et al. Metabolic epilepsy: an update. Brain Dev. 2013; 35(9):827–41. https://doi.org/10.1016/j.braindev.2012.11.010 PMID: 23273990

14. Schwarz R. The kynurenicin pathway of tryptophan degradation as a drug target. Current opinion in pharmacology. 2004; 4(1):12–7. Epub 2004/03/17. https://doi.org/10.1016/j.coph.2003.10.006 PMID: 15018833

15. Lopansri BK, Anstey NM, Stoddard GJ, Mwaikamb o ED, Boutlis CS, Tjitra E, et al. Phenylalanine in severe malaria and implications for pathophysiology of neurological complications. Infection and immunity. 2006; 74(6):3355–9. https://doi.org/10.1128/IAI.02106-05 PMID: 16714564

16. Waisbren SE, Noel K, Fahrbach K, Cella C, Dorenbaum A, et al. Phenylalanine blood levels rescues mice from late-stage cerebral malaria. Proc Natl Acad Sci U S A. 2015; 112(42):13075–80. PubMed Central PMCID: PMC4620853. https://doi.org/10.1073/pnas.1516544112 PMID: 26438846

17. Hofmann AF, Hagay LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. Journal of lipid research. 2014; 55(8):1553–95. https://doi.org/10.1194/jlr.R049437 PMID: 24838141
22. Maggiore G, Bernard O, Hadchouel M, Lemonnier A, Alagille D. Diagnostic Value of Serum [gamma]-Glutamyl Transpeptidase Activity in Liver Diseases in Children. Journal of pediatric gastroenterology and nutrition. 1991; 12(1):21–6. PMID: 1676410

23. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014; 66 (4):948–83. PubMed Central PMCID: PMC4180336. https://doi.org/10.1124/pr.113.008201 PMID: 25073467

24. Whitten R, Milner DA Jr., Yeh MM, Kamiza S, Molyneux ME, Taylor TE. Liver pathology in Malawian children with fatal encephalopathy. Human pathology. 2011; 42(9):1230–9. Epub 2011/03/15. PubMed Central PMCID: PMCPmc3137725. https://doi.org/10.1016/j.humpath.2010.11.019 PMID: 21396681

25. Greenwood J, Adu J, Davey AJ, Abbott NJ, Bradbury MW. The effect of bile salts on the permeability and ultrastructure of the perfused, energy-depleted, rat blood-brain barrier. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 1991; 11(4):644–5. Epub 1991/07/01.

26. Palmela I, Correia L, Silva RF, Sasaki H, Kim KS, Brites D, et al. Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front Neurosci. 2015; 9:80. PubMed Central PMCID: PMC4358072. https://doi.org/10.3389/fnins.2015.00080 PMID: 25821432

27. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Taurolithocholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A. 2002; 99(16):10671–6. PubMed Central PMCID: PMC125009. https://doi.org/10.1073/pnas.162320299 PMID: 12149470

28. Mitchell G, Kassovska-Bratinova S, Boukaftane Y, Robert M, Wang S, Ashmarina L, et al. Medical aspects of ketone body metabolism. Clinical and investigative medicine Medecine clinique et experimentale. 1995; 18(3):193–216. PMID: 7554586

29. Cawthorn WP, Sethi JK. TNF-α and adipocyte biology. FEBS letters. 2008; 582(1):117–31. https://doi.org/10.1016/j.febslet.2007.11.051 PMID: 18037376

30. Itse MA, Sampaio JL, Cabal GG, Real E, Zuzarte-Luis V, March S, et al. Host cell phosphatidylcholine is a key mediator of malaria parasite survival during liver stage infection. Cell host & microbe. 2014; 16 (6):778–86. PubMed Central PMCID: PMC4271766.

31. Ghosh S, Sengupta A, Sharma S, Sonawat HM. Early prediction of cerebral malaria by 1 H NMR based metabolomics. Malaria Journal. 2016; 15(1):1.

32. Sherman IW. Amino acid metabolism and protein synthesis in malarial parasites. Bulletin of the World Health Organization. 1977; 55(2–3):265–76. PubMed Central PMCID: PMC2366754. PMID: 3381833

33. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, et al. Impaired nitric oxide bioavailability and L-arginine reversibly endothelial dysfunction in adults with falciparum malaria. The Journal of experimental medicine. 2007; 204(11):2693–704. Epub 2007/10/24. PubMed Central PMCID: PMCPmc2118490. https://doi.org/10.1084/jem.20070819 PMID: 17954570

34. Sibal L, Agarwal SC, Horne PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Current cardiology reviews. 2010; 6(2):82. https://doi.org/10.2174/157340310791162659 PMID: 21532773

35. Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. American journal of respiratory and critical care medicine. 2013; 187(9):967–76. https://doi.org/10.1164/rccm.201209-1726OC PMID: 23471468

36. Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, et al. An integrated clinical-metabolomic model improves prediction of death in sepsis. Science translational medicine. 2013; 5(195):195ra95–ra95. https://doi.org/10.1126/scitranslmed.3005893 PMID: 23884467

37. Rogers AJ, McGeachie M, Baron RM, Gazourian L, Haspel JA, Nakahira K, et al. Metabolic derangements are associated with mortality in critically ill adult patients. PloS one. 2014; 9(1):e87538. https://doi.org/10.1371/journal.pone.0087538 PMID: 24498130

38. Davis JS, Darcy CJ, Yeo TW, Jones C, McNeil YR, Stephens DP, et al. Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. PloS one. 2011; 6(2):e17260. https://doi.org/10.1371/journal.pone.0017260 PMID: 213642299 PMID: 12149470

39. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, Jones C, et al. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS pathogens. 2010; 6(4):e1000868. https://doi.org/10.1371/journal.ppat.1000868 PMID: 20421938

40. Enwonwu C, Afolabi B, Salako L, Idigbe E, Bashirelahi N. Increased plasma levels of histidine and histamine in falciparum malaria: relevance to severity of infection. Journal of neural transmission. 2000; 107 (11):1273–87. https://doi.org/10.1007/s007020070017 PMID: 11145003
41. Beghdadi W, Porcherie A, Schneider BS, Morisset S, Dubayle D, Peronet R, et al. Histamine H3 receptor-mediated signaling protects mice from cerebral malaria. PLoS One. 2009; 4(6):e6004. https://doi.org/10.1371/journal.pone.0006004 PMID: 19547708

42. Lakshmanan V, Rhee KY, Wang W, Yu Y, Khaflizov K, Fiser A, et al. Metabolomic analysis of patient plasma yields evidence of plant-like α-linolenic acid metabolism in Plasmodium falciparum. Journal of Infectious Diseases. 2012; 206(2):238–48. https://doi.org/10.1093/infdis/jis339 PMID: 22566569